PharmAthene (Amex: PIP - News) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia® for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit www.PharmAthene.com.

Contact Information

One Park Place
Suite 450
Annapolis, MD 21401

tel: 410-269-2600
fax: 410-269-2601


Investor Relations



Exchange: AMEX
Industry: Diversified Investments
Market Cap: $57.4M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.